文献速递肝肾功能剂量调整治疗药物监测与药物基因组学特殊人群用药

高容量连续性静脉-静脉血液透析滤过下头孢他啶-阿维巴坦的药代动力学:首例儿科病例报告

Pharmacokinetic of ceftazidime-avibactam in a critically ill patient under high-volume continuous venovenous haemodiafiltration: A first paediatric case report.
PubMed 文献 · Br J Clin Pharmacol · 2024-01-15

本文报告一名6月龄重症联合免疫缺陷患儿在干细胞移植后发生嗜麦芽窄食单胞菌血流感染,接受高容量连续性静脉-静脉血液透析滤过期间使用头孢他啶-阿维巴坦的药代动力学。头孢他啶和阿维巴坦的总清除率分别为1.7和3.02 L/h,其中CRRT清除分别占28.8%-60%和14%-33%,高于成人文献报道,提示治疗失败和耐药风险。

要点

  • 该儿科病例中头孢他啶-阿维巴坦总清除率高于成人报道,CRRT贡献显著。
  • CRRT期间需监测抗菌药物浓度,并评估更高剂量或持续输注。

核心结论

  • 该危重患儿在CRRT下头孢他啶-阿维巴坦清除率高于成人文献报道,存在治疗失败和耐药风险。

研究设计与样本

  • 单例儿科病例报告,患者为6月龄女性,因干细胞移植后嗜麦芽窄食单胞菌血流感染接受治疗。
  • CRRT于第2天开始,采用液相色谱-串联质谱监测头孢他啶-阿维巴坦浓度。

主要发现

  • 头孢他啶和阿维巴坦的总清除率分别为1.7和3.02 L/h。
  • CRRT清除对头孢他啶的贡献为28.8%-60%,对阿维巴坦为14%-33%。

临床怎么用

  • CRRT期间应监测头孢他啶-阿维巴坦浓度,并评估更高剂量或持续输注方案。

局限性

  • 为单例病例报告,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Ceftazidime-avibactam is a novel cephalosporin/B-lactamase inhibitor developed in the context of increasing resistance. This case reports the pharmacokinetics of ceftazidime-avibactam in a critically ill child under continuous renal replacement (CRRT) therapy for fluid overload. The patient was a 6-month-old female with sepsis due to bloodstream infection to Stenotrophomonas maltophilia following stem cell transplantation for severe combined immunodeficiency. CRRT was started on Day 2. Concentrations have been monitored using liquid chromatography-tandem mass spectrometry. Treatment was given every 8 h with a 2 h infusion of 30-7,5 mg/kg and did not reach pharmacokinetic/pharmacodynamic targets. Total clearance was respectively 1.7 and 3.02 L/h, with CRRT clearance respectively 28.8%-60% for ceftazidime and 14%-33% for avibactam. Those clearances are higher than reported in adult literature leading to a risk of treatment failure and emerging resistance. This supports the benefit of monitoring antimicrobial therapy under CRRT and the necessity to assess higher dosing or continuous infusion of ceftazidime-avibactam.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Collignon C, Benaboud S, Gana I, et al. Pharmacokinetic of ceftazidime-avibactam in a critically ill patient under high-volume continuous venovenous haemodiafiltration: A first paediatric case report. Br J Clin Pharmacol. 2024. PMID: 38178624. doi:10.1111/bcp.15993

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。